Sam Hall

Sam Hall has experience in the life sciences across roles as a private equity investor, investment banker, and basic scientist. 

From 2013 until October 2019, Sam was a Partner at Apple Tree Partners (ATP), a New York-based life sciences venture capital firm with $2.5 billion under management.  At ATP Sam co-led the therapeutics investing practice and focused principally on the formation and growth of new biotechnology companies.  During his tenure Sam served as a director of ATP portfolio companies Syntimmune (acquired by Alexion Pharmaceuticals), Elstar Therapeutics, Limelight Bio and Chinook Therapeutics and he continues to serve as a director of Stoke Therapeutics (NASDAQ: STOK).  Sam also is a director of the Burke Neurological Institute, an independent neuroscience research institute affiliated with Weill Cornell Medicine.

Prior to joining ATP in 2013, Sam was a researcher at the University of Cambridge in the UK, where his work focused on novel therapeutic strategies for autoimmune diseases. Previously, Sam was a member of the investment team at Symphony Capital, a private equity firm dedicated to investments in biopharmaceutical development. Prior to Symphony, he served as a member of the healthcare investment banking team at Citigroup, where he advised leading biotechnology, medical device and healthcare services businesses on numerous completed strategic and debt and equity financing engagements.

Sam holds an A.B. in Molecular Biology from Princeton University and completed his M.Phil. and Ph.D. research at the University of Cambridge, where he was a Taylor Research Scholar and was awarded an NSF Graduate Research Fellowship for his work.